Literature DB >> 17406865

Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.

Lisa Mosconi1, Wai H Tsui, Henry Rusinek, Susan De Santi, Yi Li, Gene-Jack Wang, Alberto Pupi, Joanna Fowler, Mony J de Leon.   

Abstract

PURPOSE: To examine CMRglc measures and corresponding glucose transport (K1 and k2) and phosphorylation (k3) rates in the medial temporal lobe (MTL, comprising the hippocampus and amygdala) and posterior cingulate cortex (PCC) in mild Alzheimer's disease (AD).
METHODS: Dynamic FDG PET with arterial blood sampling was performed in seven mild AD patients (age 68+/-8 years, four females, median MMSE 23) and six normal (NL) elderly (age 69+/-9 years, three females, median MMSE 30). Absolute CMRglc (micromol/100 g/min) was calculated from MRI-defined regions of interest using multiparametric analysis with individually fitted kinetic rate constants, Gjedde-Patlak plot, and Sokoloff's autoradiographic method with population-based rate constants. Relative ROI/pons CMRglc (unitless) was also examined.
RESULTS: With all methods, AD patients showed significant CMRglc reductions in the hippocampus and PCC, and a trend towards reduced parietotemporal CMRglc, as compared with NL. Significant k3 reductions were found in the hippocampus, PCC and amygdala. K1 reductions were restricted to the hippocampus. Relative CMRglc had the largest effect sizes in separating AD from NL. However, the magnitude of CMRglc reductions was 1.2- to 1.9-fold greater with absolute than with relative measures.
CONCLUSION: CMRglc reductions are most prominent in the MTL and PCC in mild AD, as detected with both absolute and relative CMRglc measures. Results are discussed in terms of clinical and pharmaceutical applicability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17406865     DOI: 10.1007/s00259-007-0406-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

5.  A new rating scale for age-related white matter changes applicable to MRI and CT.

Authors:  L O Wahlund; F Barkhof; F Fazekas; L Bronge; M Augustin; M Sjögren; A Wallin; H Ader; D Leys; L Pantoni; F Pasquier; T Erkinjuntti; P Scheltens
Journal:  Stroke       Date:  2001-06       Impact factor: 7.914

6.  Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.

Authors:  Lisa Mosconi; Susan De Santi; Yi Li; Juan Li; Jiong Zhan; Wai Hon Tsui; Madhu Boppana; Alberto Pupi; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-26       Impact factor: 9.236

7.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

8.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

9.  Diminished glucose transport in Alzheimer's disease: dynamic PET studies.

Authors:  W J Jagust; J P Seab; R H Huesman; P E Valk; C A Mathis; B R Reed; P G Coxson; T F Budinger
Journal:  J Cereb Blood Flow Metab       Date:  1991-03       Impact factor: 6.200

10.  MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Authors:  L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

View more
  17 in total

1.  Metabolic control of resting hemispheric cerebral blood flow is oxidative, not glycolytic.

Authors:  William J Powers; Tom O Videen; Joanne Markham; Vonn Walter; Joel S Perlmutter
Journal:  J Cereb Blood Flow Metab       Date:  2011-02-09       Impact factor: 6.200

2.  Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.

Authors:  Sepideh Shokouhi; Desmond Campbell; Aaron B Brill; Harry E Gwirtsman
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

3.  Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats.

Authors:  Wenqing Yang; Jing Ma; Zheng Liu; Yongliang Lu; Bin Hu; Huarong Yu
Journal:  Neurol Sci       Date:  2013-12-12       Impact factor: 3.307

4.  Influence of the partial volume correction method on (18)F-fluorodeoxyglucose brain kinetic modelling from dynamic PET images reconstructed with resolution model based OSEM.

Authors:  Spencer L Bowen; Larry G Byars; Christian J Michel; Daniel B Chonde; Ciprian Catana
Journal:  Phys Med Biol       Date:  2013-09-20       Impact factor: 3.609

Review 5.  Impact of Genetic Risk Factors for Alzheimer's Disease on Brain Glucose Metabolism.

Authors:  Sukhee Cho; Hyein Lee; Jinsoo Seo
Journal:  Mol Neurobiol       Date:  2021-01-21       Impact factor: 5.590

Review 6.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

7.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

8.  Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease.

Authors:  Fei Liu; Jianhua Shi; Hitoshi Tanimukai; Jinhua Gu; Jianlan Gu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Brain       Date:  2009-05-18       Impact factor: 13.501

9.  Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-accelerated prone mouse strain 8 (SAMP8).

Authors:  Xuezhu Zhang; Guomin Li; Lin Guo; Kun Nie; Yujie Jia; Lan Zhao; Jianchun Yu
Journal:  Neurol Sci       Date:  2013-04-07       Impact factor: 3.307

10.  Resting-state glucose metabolism level is associated with the regional pattern of amyloid pathology in Alzheimer's disease.

Authors:  Jonghan Shin; Wai Tsui; Yi Li; Sang-Yoon Lee; Seog Ju Kim; Seong-Jin Cho; Young-Bo Kim; Mony J de Leon
Journal:  Int J Alzheimers Dis       Date:  2011-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.